ARS Pharmaceuticals (SPRY) Interest Expenses (2026)

ARS Pharmaceuticals has reported Interest Expenses for 7 years, with the latest figure at $35.6 million in Q1 2026.

• Quarterly Interest Expenses rose 323218.18% year-over-year to $35.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.6 million (up 323218.18% YoY) and the FY2025 annual result came in at $78.2 million, up 9.32% from the prior year.
• Interest Expenses advanced to $35.6 million in Q1 2026 per SPRY's latest filing, from $2.2 million in the prior quarter.
• Over five years, Interest Expenses peaked at $39.4 billion in Q1 2023 and troughed at -$184000.0 in Q4 2024.
• A 5-year average of $5.8 billion and a median of $43.8 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 875193.2% in 2023, then slumped 99.99% in 2025.
• Over 5 years, Interest Expenses stood at $100000.0 in 2022, then surged by 15442325.0% to $15.4 billion in 2023, then sank by 100.0% to -$184000.0 in 2024, then jumped by 1287.5% to $2.2 million in 2025, then jumped by 1527.69% to $35.6 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $35.6 million, $2.2 million, and $59.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.